Table 4 Performance characteristics of POCTs for NG compared to reference assays (meta-analysis data)
| Â | Â | Pharynx | Rectum | Urine | |||
|---|---|---|---|---|---|---|---|
| Â | n | Sensitivity (%) | Specificity (%) | Sensitivity (%) | Specificity (%) | Sensitivity (%) | Specificity (%) |
Italy | 299 | 75.00 (42.81–94.51) | 98.25 (95.97–99.43) | 100 (78.20–100) | 99.64 (98.01–99.99) | 87.5 (47.35–99.68) | 100 (98.74–100) |
Malta | 742 | 84.09 (69.93–93.36) | 99.42 (98.51–99.84) | 85.11 (71.69–93.80) | 99.42 (98.51–99.84) | 93.75 (69.77–99.84) | 99.71 (98.96–99.97) |
Peru1 | 267 | 73.08 (52.21–88.43) | 98.74 (96.38–99.74) | 91.67 (73.00–98.97) | 99.56 (97.58–99.99) | 83.33 (35.88–99.58) | 99.23 (97.25–99.91) |
Peru2 | 394 | 66.67 (47.19–82.71) | 98.05 (96.02–99.21) | 90.00 (76.34–97.21) | 99.71 (98.42–99.99) | 100 (47.82–100) | 100.00 (99.05–100.00) |
Fixed effects model | 75.89 (65.42–83.97) | 98.79 (97.95–99.28) | 89.68 (81.56–94.47) | 99.55 (98.92–99.81) | 91.43 (72.61–97.72) | 99.75 (99.23–99.92) | |
Random effects model | 75.87 (66.90–83.03) | 98.77 (97.94–99.27) | 89.68 (83.03–93.92) | 99.55 (99.05–99.78) | 91.43 (76.54–97.21) | 99.75 (99.35–99.91) | |
|  |  | Between sites variability—SD (p-value) | Between sites variability—SD (p-value) | Between sites variability—SD (p-value) | |||
| Â | Â | 7.08 (0.97) | 7.19 (0.69) | - | - | Â | Â |
|  |  | DOR | 253.57 (127.48–504.37) | DOR | 1903.61 (743.87–4871.45) | DOR | 4338.67 (930.91–20.221.17) |
|  |  | LR +  | 61.94 (36.42–105.33) | LR +  | 197.30 (93.91–414.52) | LR +  | 372.80 (139.19–998.51) |
|  |  | LR- | 0.24 (0.17–0.34) | LR- | 0.10 (0.06–0.17) | LR- | 0.09 (0.03–0.25) |